0000950170-23-026500.txt : 20230605 0000950170-23-026500.hdr.sgml : 20230605 20230605200733 ACCESSION NUMBER: 0000950170-23-026500 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230601 FILED AS OF DATE: 20230605 DATE AS OF CHANGE: 20230605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bodenrader Mark CENTRAL INDEX KEY: 0001830371 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 23994595 MAIL ADDRESS: STREET 1: C/O CEREVEL THERAPEUTICS HOLDINGS INC. STREET 2: 131 DARTMOUTH STREET SUITE 502 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 ownership.xml 4 X0407 4 2023-06-01 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001830371 Bodenrader Mark C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 false true false false See Remarks true Common Stock 2023-06-01 4 M false 4733 A 7417 D Common Stock 2023-06-02 4 S false 1895 32.95 D 5522 D Restricted Stock Units 2023-06-01 4 M false 4733 0.00 D Common Stock 4733 14199 D Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. Includes 2,684 shares previously acquired under the Issuer's Employee Stock Purchase Plan. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and intended to qualify under Rule 10b5-1. On June 1, 2022, the Reporting Person was granted 18,932 RSUs under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. 25% of the RSUs vest on each of the first, second, third and fourth anniversary of June 1, 2022, subject to the Reporting Person's continued service relationship with the Issuer through each such date. Title: Senior Vice President, Finance and Chief Accounting Officer /s/ Mark Bodenrader 2023-06-05